Results of treatment of chronic hepatitis B with pegylated interferon

Mauro Viganò, Giampaolo Mangia, Pietro Lampertico

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.

Original languageEnglish
Pages (from-to)425-443
Number of pages19
JournalClinics in Liver Disease
Volume17
Issue number3
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Chronic Hepatitis B
Interferons
Therapeutics
Hepatitis B Surface Antigens
Patient Selection
Disease Progression
Infection

Keywords

  • Chronic hepatitis B
  • HBsAg levels
  • HBV DNA
  • IL28B polymorphism
  • Pegylated interferon
  • Sustained response

ASJC Scopus subject areas

  • Hepatology

Cite this

Results of treatment of chronic hepatitis B with pegylated interferon. / Viganò, Mauro; Mangia, Giampaolo; Lampertico, Pietro.

In: Clinics in Liver Disease, Vol. 17, No. 3, 08.2013, p. 425-443.

Research output: Contribution to journalArticle

Viganò, Mauro ; Mangia, Giampaolo ; Lampertico, Pietro. / Results of treatment of chronic hepatitis B with pegylated interferon. In: Clinics in Liver Disease. 2013 ; Vol. 17, No. 3. pp. 425-443.
@article{68a7e55f68d34bbc9d79b41ed09d539f,
title = "Results of treatment of chronic hepatitis B with pegylated interferon",
abstract = "Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.",
keywords = "Chronic hepatitis B, HBsAg levels, HBV DNA, IL28B polymorphism, Pegylated interferon, Sustained response",
author = "Mauro Vigan{\`o} and Giampaolo Mangia and Pietro Lampertico",
year = "2013",
month = "8",
doi = "10.1016/j.cld.2013.05.004",
language = "English",
volume = "17",
pages = "425--443",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Results of treatment of chronic hepatitis B with pegylated interferon

AU - Viganò, Mauro

AU - Mangia, Giampaolo

AU - Lampertico, Pietro

PY - 2013/8

Y1 - 2013/8

N2 - Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.

AB - Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.

KW - Chronic hepatitis B

KW - HBsAg levels

KW - HBV DNA

KW - IL28B polymorphism

KW - Pegylated interferon

KW - Sustained response

UR - http://www.scopus.com/inward/record.url?scp=84881025752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881025752&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2013.05.004

DO - 10.1016/j.cld.2013.05.004

M3 - Article

VL - 17

SP - 425

EP - 443

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -